ResearcherTianjin Nankai HospitalActive in the last 2 years

Jing Xun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8730-4212; OpenAlex author ID A5033350690. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic cancer. Co-author DOI 10.1016/j.intimp.2024.112696 ↗
The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms. Co-author DOI 10.1590/1414-431x2022e12324 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qi Zhang · 1 shared paper, 2024 · strength 0.19
- Paper Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic c… DOI 10.1016/j.intimp.2024.112696 ↗
Ximo Wang · 1 shared paper, 2024 · strength 0.19
- Paper Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic c… DOI 10.1016/j.intimp.2024.112696 ↗
Zhaoyong Yang · 1 shared paper, 2022 · strength 0.17
- Paper The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms. DOI 10.1590/1414-431x2022e12324 ↗
Lihua Cui · 1 shared paper, 2022 · strength 0.17
- Paper The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms. DOI 10.1590/1414-431x2022e12324 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.